Inflammation and Cancer
Chronic and or low-grade inflammation is suspected to have many tumour promoting effects.
- It aids in the proliferation and survival of malignant cells
- It promotes angiogenesis and metastasis,
- It subverts adaptive immune responses,
- It alters cellular responses to hormones and chemotherapeutic agents.
The connection between inflammation and cancer can be viewed as consisting of two pathways, an external pathway that is driven by external factors such as inflammatory disease, and an internal pathway, driven by genetic changes that promote tumour formation. When the two pathways meet, it results in the activation of transcription factors, mainly nuclear factor-κB (NF-κB), signal transducer and activator of transcription 3 (STAT3) and hypoxia-inducible factor 1α (HIF1α), in tumour cells. In turn, these transcription factors promote the synthesis of inflammatory mediators, including cytokines and chemokines, as well as the production of cyclooxygenase 2 (COX2) and of prostaglandins. Leukocytes such as neutrophils and macrophages are recruited to the tumour by these signals, generating a cancer causing microenvironment.
In Vitro Technologies offers cutting-edge tools to study the emerging links between immune cell mediated inflammation and cancer, both in the tumour microenvironment and in the whole organism.
Choose R&D Systems ELISA kits and Luminex Assays to quantify circulating levels of pro-inflammatory cytokines.
In Vitro and R&D Systems also offer traditional single analyte ELISA to quantify inflammatory cytokines.
Receive 50% off your first order of a Human XL Cytokine Discovery Luminex High Performance Assay or a free Duoset ancillary kit.
Valid to April 30.
Fill out your details on the form to Access your Offer CODE.
What’s in your sample?
Cell Resource
Click on the images below to find out more about other immune cell types.
